SUSAN BOEHNKE: Open Payments
NPI 1033692843 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,352 in 22 payments from 14 companies in 2025. Trend: 2023 $366 · 2024 $1,162 · 2025 $1,352
Food & beverage: $1,352
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 4 | $297 |
| ABBVIE INC. | 3 | $147 |
| Aimmune Therapeutics, Inc. | 1 | $125 |
| Ardelyx, Inc. | 1 | $124 |
| Corcept Therapeutics | 1 | $123 |
| Celltrion USA Inc. | 1 | $120 |
| Axsome Therapeutics, Inc. | 1 | $117 |
| Phathom Pharmaceuticals, Inc. | 1 | $113 |
| Regeneron Healthcare Solutions, Inc. | 3 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $48 |
Products named: DUPIXENT, ZENPEP, RINVOQ, IBSRELA, Korlym, CERDELGA, VEGZELMA, Auvelity.
Industry payments across TX — which companies pay providers there.
